Xenon and Genentech have successfully discovered and identified a novel pain target by leveraging Xenon’s Extreme Genetics platform based on the study of rare phenotypes of individuals who
Perrigo said that its Board of Directors has reviewed Mylan’s unsolicited tender offer to acquire all of the outstanding shares of Perrigo and, in consultation with its financial
National Association of Chain Drug Stores (NACDS) President and CEO Steven C. Anderson, IOM, CAE, issued a statement about the U.S. House of Representatives Ways and Means Committee’s
DTC Eligibility allows for a Company’s securities to be traded electronically between brokerage accounts in the U.S. M Pharmaceutical CEO Matthew Lehman said: "DTC Eligibility is a significant
Appreciating the importance of the U.S. biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc.
It is the result of over 150 million euro worth of investment with creation of 100 highly skilled jobs. In attendance at the event were Austrian dignitaries from
The NDS will be reviewed with advance consideration under the Health Canada policy of Notice of Compliance with Conditions (NOC/c). If approved, Translarna would be the first treatment
The alliance will combine Clinigen’s and Cumberland’s respective strengths, expertise and geographical footprints to maximize the commercial potential of future products. As part of Clinigen’s continuing strategy to
his announcement was made at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, September 16-19, 2015 in New York, NY. VISTA (V-Domain Ig Suppressor of
Amgen has agreed to acquire all outstanding shares of Dezima for up to $1.55bn from Forbion and other current shareholders, subject to obtaining U.S. Federal Trade Commission clearance.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.